REGN7508 for Preventing Blood Clots After Knee Replacement
This study is testing an experimental drug called REGN7508 against a common treatment, Acetylsalicylic Acid (ASA), also known as aspirin. The goal is to see how well REGN7508 prevents blood clots (Venous Thromboembolism or VTE) and other related health issues after total knee replacement surgery. You might be able to join if you are an adult having elective, single-side total knee replacement surgery and are in good health. The main way we'll know if the study is successful is by looking at how many people experience VTE or death from any cause up to 30 days after their surgery. This study is currently recruiting about 2000 participants.
- Study design
- This is an interventional study comparing REGN7508, Acetylsalicylic Acid (ASA), and a placebo. It plans to enroll 2000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed through a 30-day visit after their surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
At a glance
Conditions
Where it's being run
34 sites across 21 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of the composite endpoint of symptomatic VTE and all-cause deathThrough day 30 visit